Cargando…

Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines

It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible preventi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamshidi, Elham, Asgary, Amirhossein, Shafiekhani, Paria, Khajeamiri, Yasaman, Mohamed, Kawthar, Esmaily, Hadi, Jamal Rahi, Sahand, Mansouri, Nahal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115789/
https://www.ncbi.nlm.nih.gov/pubmed/35417285
http://dx.doi.org/10.1080/21645515.2022.2037384
_version_ 1784709991439007744
author Jamshidi, Elham
Asgary, Amirhossein
Shafiekhani, Paria
Khajeamiri, Yasaman
Mohamed, Kawthar
Esmaily, Hadi
Jamal Rahi, Sahand
Mansouri, Nahal
author_facet Jamshidi, Elham
Asgary, Amirhossein
Shafiekhani, Paria
Khajeamiri, Yasaman
Mohamed, Kawthar
Esmaily, Hadi
Jamal Rahi, Sahand
Mansouri, Nahal
author_sort Jamshidi, Elham
collection PubMed
description It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccineʻs antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively.
format Online
Article
Text
id pubmed-9115789
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-91157892022-05-18 Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines Jamshidi, Elham Asgary, Amirhossein Shafiekhani, Paria Khajeamiri, Yasaman Mohamed, Kawthar Esmaily, Hadi Jamal Rahi, Sahand Mansouri, Nahal Hum Vaccin Immunother Coronavirus – Review It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccineʻs antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively. Taylor & Francis 2022-04-13 /pmc/articles/PMC9115789/ /pubmed/35417285 http://dx.doi.org/10.1080/21645515.2022.2037384 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Coronavirus – Review
Jamshidi, Elham
Asgary, Amirhossein
Shafiekhani, Paria
Khajeamiri, Yasaman
Mohamed, Kawthar
Esmaily, Hadi
Jamal Rahi, Sahand
Mansouri, Nahal
Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines
title Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines
title_full Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines
title_fullStr Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines
title_full_unstemmed Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines
title_short Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines
title_sort longevity of immunity following covid-19 vaccination: a comprehensive review of the currently approved vaccines
topic Coronavirus – Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115789/
https://www.ncbi.nlm.nih.gov/pubmed/35417285
http://dx.doi.org/10.1080/21645515.2022.2037384
work_keys_str_mv AT jamshidielham longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines
AT asgaryamirhossein longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines
AT shafiekhaniparia longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines
AT khajeamiriyasaman longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines
AT mohamedkawthar longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines
AT esmailyhadi longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines
AT jamalrahisahand longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines
AT mansourinahal longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines